China Liver Cancer Clinical Registry Cohort Database (HEAL)

Recruiting

• Conditions: Liver Cancer
• Interventions: Procedure: Procedure/Surgery treatment; Drug: Anti-Tumor Drugs

• Registration Number: NCT06777485
• Lead Sponsor: Anhui Provincial Hospital

Brief Summary

This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-01-01
• Study First Submitted: 2025-01-14
• Study First Submitted QC: 2025-01-14
• Study First Posted: 2025-01-15
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-15
• Last Update Posted: 2025-08-20
• Primary Completion: 2035-01-01
• Study Completion: 2035-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

• Age ≥ 18 years, no gender limit
• Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
• Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples

Exclusion Criteria

• Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
• Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
• Pregnant or breastfeeding women
• Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Liver Cancer	Procedure/Surgery treatment	Observation of clinical routine treatment in patients with Liver cancer
Liver Cancer	Anti-Tumor Drugs	Observation of clinical routine treatment in patients with Liver cancer

Primary Outcome Measures

Name	Time	Method
OS	10 years	Time from enrollment to first recorded occurrence of death from any cause

Secondary Outcome Measures

Name	Time	Method
RFS	10 years	Time from enrollment to the first documented occurrence of local, regional, or metastatic liver cancer or death from any cause, whichever occurs first.
Survival time after recurrence	10 years	The time from the first documented occurrence of localized, regional, or metastatic liver cancer, whichever occurs first, to death from any cause.

Trial Locations

Locations (38)

Anqing First People's Hospital; 🇨🇳 Anqing, Anhui, China

Anqing Municipal Hospital; 🇨🇳 Anqing, Anhui, China

Bengbu First People's Hospital; 🇨🇳 Bengbu, Anhui, China

The First Affiliated Hospital of Bengbu Medical University; 🇨🇳 Bengbu, Anhui, China

The Second Affiliated Hospital of Bengbu Medical College; 🇨🇳 Bengbu, Anhui, China

The People's Hospital of Bozhou; 🇨🇳 Bozhou, Anhui, China

The People's Hospital of Chizhou; 🇨🇳 Chizhou, Anhui, China

The First People's Hospital of Chuzhou; 🇨🇳 Chuzhou, Anhui, China

No.2 People's Hospital of Fuyang City; 🇨🇳 Fuyang, Anhui, China

Fuyang Cancer Hospital; 🇨🇳 Fuyang, Anhui, China

Scroll for more (28 remaining)